In a new analysis of Phase 2 and 3 anifrolumab (Saphnelo®) clinical trial data, researchers found that the SLE Disease ...
Women with systemic lupus erythematosus who receive immunosuppressive therapy show a higher prevalence of cervical lesions and cervical human papillomavirus infection than immunocompetent women.
Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus ...
Filing acceptance based on Phase III ALLEGORY data for Gazyva showing a significant reduction in disease activity compared with placebo in people with systemic lupus erythematosus (SLE)If approved, ...
The U.S. Food and Drug Administration (FDA) has accepted Genentech’s supplemental Biologics License Application for Gazyva® ...
Sixth paragraph, fifth sentence of release issued April 20, 2026 at 10 p.m. PT/April 21, 2026 at 1 a.m. ET, should read: In addition, treatment with Gazyva plus standard therapy, versus placebo plus ...
US FDA accepts Roche’s sBLA for Gazyva/Gazyvaro for the treatment of systemic lupus erythematosus: Basel Wednesday, April 22, 2026, 09:00 Hrs [IST] Roche announced that the US F ...
Filing acceptance based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a significant reduction in disease activity ...
Germany had opened applications for a fully funded SLE programme at Humboldt University, offering scholarships and training ...
Supported by the phase 3 ALLEGORY trial, the application moves obinutuzumab closer to becoming a new standard for patients with active, autoantibody-positive SLE.
Over the past decade, InnoCare has achieved remarkable results. 2026 marks the beginning of the Company’s next golden decade of development. Driven by its outstanding performance in 2025, the Company ...
Objective Cardiovascular diseases are a leading cause of morbidity and mortality in SLE. In this target population, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results